DnB Asset Management AS Has $91,000 Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

DnB Asset Management AS trimmed its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 36.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,298 shares of the company’s stock after selling 9,390 shares during the quarter. DnB Asset Management AS’s holdings in 4D Molecular Therapeutics were worth $91,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new position in 4D Molecular Therapeutics during the fourth quarter worth about $48,000. PNC Financial Services Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after purchasing an additional 9,737 shares during the period. Fox Run Management L.L.C. acquired a new stake in 4D Molecular Therapeutics during the 4th quarter worth approximately $69,000. Finally, AlphaQuest LLC increased its position in shares of 4D Molecular Therapeutics by 3,665.2% during the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock worth $83,000 after acquiring an additional 14,441 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on FDMT shares. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Chardan Capital decreased their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Morgan Stanley reduced their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. Finally, Leerink Partners dropped their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.71.

4D Molecular Therapeutics Stock Up 9.7 %

FDMT opened at $3.28 on Thursday. The stock has a market cap of $151.87 million, a price-to-earnings ratio of -1.15 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.87 and a 12-month high of $29.27. The business has a 50 day moving average of $4.49 and a 200-day moving average of $6.77.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.